Medicines

Since 1996, 95 new medicines for use in oncology have been approved by the European Medicines Agency. Despite this, the newest cancer drugs make up only 8% of average cancer medicine sales across Europe, which varies between 4% and 11% per year in different European countries.

The UK has one of the lowest uptake rates of new cancer medicines compared with the four largest European economies - Germany, France, Italy and Spain - for all the medicines analysed. This means that between 2009 and 2014, treatment options for cancer patients in the UK have often lagged behind those in other European countries.

The Cancer Drugs Fund (CDF) was introduced in October 2010 to address low access for NHS patients to new cancer medicines, use of which was then 33% below the European average. In July 2016 the CDF was reformed into a managed access fund. The assessment of medicines in the new CDF uses the same methodology that necessitated the creation of the CDF in the first place. There is not yet data to show whether the original CDF improved patient outcomes, particularly for survival, but studies suggest that patient access to optimal treatment improves outcomes.

The medicines in this section are analysed in the Institute of Health Economics' Comparator Report and correspond to some of the most widely used medicines for each cancer in 2014.

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2

Jönsson, B. Hofmarcher T., Lindgren, P., Wilking, N., Comparator report on patient access to medicines in Europe revisited, 2016. Available at http://ihe.se/en/publicering/cancer-medicines-in-europe-2